GFRAL Silencing in Cancer Cachexia Prolonged Mouse Survival

GFRAL silencing in cancer cachexia helped mice preserve muscle and fat, regain strength, and survive longer with aggressive tumors. The intervention did not target the tumor or the muscle itself. Instead, it reduced production of a receptor in the hindbrain, highlighting the brain’s active role in cancer-associated wasting. The findings are preclinical and do not yet establish a treatment for people.

Cachexia is more than weight loss caused by poor appetite. It is a systemic syndrome in which skeletal muscle and fat are progressively depleted, metabolism is disrupted, and nutritional support alone often cannot reverse the decline. The resulting weakness can reduce tolerance of anticancer therapy and is associated with a worse prognosis.

How a tumor sends a wasting signal to the brain

One mediator of this process is growth differentiation factor 15, or GDF15. Its concentration can rise sharply in cancer and other severe illnesses. Carried in the bloodstream, GDF15 reaches small regions of the hindbrain that can detect chemical signals from the body.

There it binds to GFRAL, a receptor found mainly in the area postrema and the neighboring nucleus of the solitary tract. These regions help regulate appetite, nausea, and autonomic responses. Activating the GDF15–GFRAL pathway reduces food intake, but its effects are not limited to hunger: the signal is also linked to increased use of the body’s energy stores.

The South Korean team chose to reduce the receptor rather than neutralize circulating GDF15. They developed A427, an antisense oligonucleotide designed to bind Gfral messenger RNA. An antisense oligonucleotide is a short synthetic nucleic-acid strand that recognizes a specific RNA sequence. Once bound, it prevents the cell from using that RNA normally, reducing production of the encoded protein.

The researchers gave a single dose directly into a brain ventricle of mice that had already developed severe cachexia. They tested the approach in mouse models of MC38 colon cancer and KPC and MPC1 pancreatic cancers. Using several tumor models allowed them to assess whether the effect was restricted to one particular cancer system.

What changed after GFRAL was reduced

A427 markedly lowered GFRAL expression in the hindbrain. It also reduced pathological neuronal activation, measured through the activity marker c-Fos, in the area postrema and nucleus of the solitary tract. The tumor-associated signal was still present in the body, but the relevant neural centers responded less strongly.

The treated animals stopped losing, or regained, body weight. They retained more skeletal muscle and adipose tissue, and their grip strength improved. For this functional measure, Gfral silencing produced a greater rescue than a systemically administered antibody that neutralized GDF15.

The most consequential finding was longer survival. In one experiment, about 90% of mice treated with the antisense oligonucleotide were alive at roughly day 50, compared with about 20% of control animals. This does not show that the intervention killed the cancer. A more restrained interpretation is that preserving muscle, fat, and physical function enabled the animals to withstand advanced disease for longer.

The study also helps explain why additional calories alone often fail to correct cachexia. As long as the central nervous system continues to promote reduced feeding and depletion of energy reserves, nutritional support does not remove the underlying signal. Reducing GFRAL altered the body’s systemic response to the tumor, not merely the amount of food consumed.

A long path remains before human treatment

The central limitation is the delivery method. A427 was injected directly into a brain ventricle. That route is useful for demonstrating a mechanism in mice, but it is too invasive for routine treatment. A clinically practical strategy would need to reach the relevant hindbrain cells safely and selectively, while establishing an appropriate dose, duration of action, and safety profile.

The GDF15–GFRAL pathway is also part of the normal response to physiological stress and tissue injury. Prolonged suppression could therefore have consequences that short animal experiments do not reveal. It remains unknown whether the approach would work across the diversity of human cancers, disease stages, and treatment regimens.

A427 should not be described as a ready therapy for cancer cachexia. Its importance is more fundamental: the brain may not merely register tumor-associated wasting but help sustain it. If this signal can eventually be interrupted safely, cachexia might be treated as a distinct component of cancer rather than managed only through its downstream consequences.